



Contents lists available at ScienceDirect

International Journal of Infectious Diseases

journal homepage: www.elsevier.com/locate/ijid



Device-associated infection rates in 398 intensive care units in Shanghai, China: International Nosocomial Infection Control Consortium (INICC) findings

Lili Tao^a, Bijie Hu^{a,*}, Victor D. Rosenthal^b, Xiaodong Gao^a, Lixian He^a

^a Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Rd, Shanghai, 200032, China

^b International Nosocomial Infection Control Consortium, Buenos Aires, Argentina

ARTICLE INFO

Article history:

Received 4 January 2011
Received in revised form 11 June 2011
Accepted 20 June 2011

Corresponding Editor: Mark Holodniy, California, USA

Keywords:

International Nosocomial Infection Control Consortium (INICC)
Central line-associated blood stream infection
Ventilator-associated pneumonia
Catheter-associated urinary tract infection
China
Developing country
Device-associated healthcare-associated

SUMMARY

Objectives: To determine device-associated healthcare-associated infection (DA-HAI) rates and the microorganism profile in 398 intensive care units (ICUs) of 70 hospitals in Shanghai, China.

Methods: An open-label, prospective, cohort, active DA-HAI surveillance study was conducted on patients admitted to 398 tertiary-care ICUs in China from September 2004 to December 2009, implementing the methodology developed by the International Nosocomial Infection Control Consortium (INICC). The data were collected in the participating ICUs, and uploaded and analyzed at the INICC headquarters on proprietary software. DA-HAI rates were registered by applying the definitions of the US Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN). We analyzed the rates of DAI-HAI, ventilator-associated pneumonia (VAP), central line-associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI), and their microorganism profiles.

Results: During the 5 years and 4 months of the study, 391 527 patients hospitalized in an ICU for an aggregate of 3 245 244 days, acquired 20 866 DA-HAIs, an overall rate of 5.3% (95% confidence interval (CI) 5.3–5.4) and 6.4 (95% CI 6.3–6.5) infections per 1000 ICU-days. VAP posed the greatest risk (20.8 per 1000 ventilator-days, 95% CI 20.4–21.1), followed by CAUTI (6.4 per 1000 catheter-days, 95% CI 6.3–6.6) and CLABSI (3.1 per 1000 catheter-days, 95% CI 3.0–3.2). The most common isolated microorganism was *Acinetobacter baumannii* (19.1%), followed by *Pseudomonas aeruginosa* (17.2%), *Klebsiella pneumoniae* (11.9%), and *Staphylococcus aureus* (11.9%).

Conclusions: DA-HAIs in the ICUs of Shanghai pose a far greater threat to patient safety than in ICUs in the USA. This is particularly the case for the VAP rate, which is much higher than the rates found in developed countries. Active infection control programs that carry out infection surveillance and implement prevention guidelines can improve patient safety and must become a priority.

© 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

1. Introduction

Surveillance of device-associated healthcare-associated infection (DA-HAI) in the intensive care unit (ICU) represents a prominent tool in hospital infection control and quality assurance in many industrialized countries, including the USA.¹ In this respect, the US Centers for Disease Control and Prevention (CDC) Study of the Efficacy of Nosocomial Infection Control (SENIC) has reported that surveillance plays a leading role in the reduction of DA-HAIs.²

Similarly, it has been increasingly reported in scientific studies that DA-HAIs pose the primary threat to patient safety in the ICU,

and are among the principal causes of patient morbidity and mortality.^{3–5} The CDC's previous National Nosocomial Infection Surveillance System (NNIS) and current National Healthcare Safety Network (NHSN) have established standardized criteria for DA-HAI surveillance.^{6,7} This standardized surveillance method allows infection control practitioners (ICPs) to determine DA-HAI rates per 1000 device-days, which can be used as benchmarks among different healthcare centers. It also provides ICPs with an in-depth look at the institutional problems they are confronted with, so that they can design an effective strategy to solve them. The device utilization (DU) ratio constitutes an extrinsic risk factor for DA-HAI.⁸ The DU ratio also comprises a marker for severity of illness in patients vis-à-vis patient susceptibility to DA-HAI. In the context of an expanded framework for DA-HAI control, it is in high-income countries that most of the relevant studies of ICU-acquired infections have been conducted;⁹ in the developing countries,

* Corresponding author.

E-mail address: hubijie@vip.sina.com (B. Hu).

37 the scientific literature reporting on DA-HAI rates by means of
38 using standardized definitions is scarce.^{10–18}

39 The International Nosocomial Infection Control Consortium
40 (INICC) was founded in 1998, after selected hospitals from Latin
41 America were invited to participate in the project to measure DA-
42 HAI using standardized definitions and methodology.¹⁹ Shortly
43 afterwards, other hospitals located in different parts of the world
44 joined the Consortium. At present, the INICC comprises a
45 worldwide network with hospitals in 40 countries of Latin
46 America, Asia, Africa, and Europe.^{10–18}

47 On a monthly basis, healthcare facilities send data to the INICC,
48 which are then entered into an international database. Hospital
49 members of the INICC provide general medical and surgical
50 inpatient services to adults and children hospitalized in the ICUs.

51 In China, published data on DA-HAI rates are not available in the
52 English language. The findings of the present study in Shanghai
53 form an integral part of the INICC and reflect the outcome
54 surveillance data that were systematically collected.

55 2. Methods

56 2.1. Setting

57 This study was carried out in 398 ICUs of 70 hospitals, from
58 September 2004 to December 2009. The hospitals have an infection
59 control team composed of physicians and ICPs with experience in
60 infection control. The infection control teams include at least one
61 full time physician and several infection control nurses. The
62 nurses involved are all professionals and work full-time in infection
63 control. They are responsible for collecting information from
64 patients, and once a DAI is suspected, they report it to the physician
65 for an immediate diagnosis. The ICPs listed in Table 1 work full time,
66 but at each hospital there are also several part-time nurses who also
67 collaborate in the diagnosis of DAI. The ICPs in Shanghai are all trained
68 by the Municipal Infection Control Center. This center provides
69 training courses twice a year, and each course lasts approximately
70 3–5 days. The performances of the ICPs in these 70 hospitals are
71 assessed by the Municipal Infection Control Center each year.

72 The clinical microbiology laboratory provides in vitro suscep-
73 tibility testing of clinical isolates using standardized methods. All
74 the hospitals analyzed the samples in their own microbiology
75 laboratories. This analysis included routine culture of the speci-
76 mens and conventional phenotypic identification using automat-
77 ed machines (BD Phoenix or VITEK 2) or API strips. The sensitivity
78 of the microorganisms was defined by the automated machines
79 (BD Phoenix or VITEK 2) or by drug sensitive slips method.

80 The nurse-to-patient ratio is 2–2.5:1 in the participating ICUs,
81 as required by the Quality Control Center of Critical Medicine and
82 Infection Control. The institutional review boards of the hospitals
83 approved the study protocol. Patient confidentiality was protected
84 by codifying the recorded information, making it only identifiable
85 to the infection control team.

86 Fifty-one percent of the participating hospitals are categorized
87 as ‘complexity level 2’ (which means that they are hospitals in

medium-size cities, counties, or districts, with more than 100 beds,
but fewer than 500), and 49% as ‘complexity level 3’ (general or
comprehensive hospital at the national, provincial, or city level,
with more than 500 beds) (Table 1)

2.2. Surveillance

On a daily basis, data were collected by the infection control
teams prospectively from all the patients admitted to the ICUs by
means of specifically designed forms for the DA-HAI definitions
provided by the CDC-NNIS and CDC-NHSN.^{6,7}

ICUs were stratified into types according to the patient
population: adult ICU or pediatric ICU.

The identity of all INICC Shanghai hospitals is confidential, in
accordance with the INICC Charter.

Device-days consisted of the total number of central line
(CL)-days, urinary catheter (UC)-days, or mechanical ventilator
(MV)-days.

2.3. DA-HAI rate calculations

Outcomes measured during the surveillance period included
the incidence density rate of central line-associated blood stream
infection (CLABSI; number of CLABSI divided by 1000 CL-days
and multiplied by 1000); catheter-associated urinary tract
infection (CAUTI; number of CAUTI divided by 1000 UC-days
and multiplied by 1000); and ventilator-associated pneumonia
(VAP; number of VAP divided by 1000 MV-days and multiplied
by 1000).

DU ratios were calculated by dividing the total number of
device-days by the total number of bed-days.²⁰

2.4. Statistical analysis

EpiInfo version 6.04b (CDC, Atlanta, GA, USA) and SPSS 16.0
(SPSS Inc. an IBM company, Chicago, IL, USA) were used to perform
the data analysis.

Chi-square analyses for dichotomous variables and the *t*-test for
continuous variables were used to analyze baseline differences
among rates. Relative risk (RR) ratios, 95% confidence intervals
(CIs), and *p*-values were determined for all outcomes. The level of
significance was set at $p < 0.05$.

3. Results

During the 5 years and 4 months of the study, 391 527 patients
hospitalized in an ICU for an aggregate of 3 245 244 days acquired
20 866 DA-HAIs, an overall rate of 5.3% (95% CI 5.3–5.4) of DA-HAIs
and 6.4 (95% CI 6.3–6.5) DA-HAIs per 1000 ICU-days. The
characteristics of the 398 ICUs at INICC Shanghai hospitals that
contributed data to this report are shown in Table 1.

The overall CLABSI rate was 3.1 (95% CI 3.0–3.2). The highest
CLABSI rate was found in the medical ICUs: 4.3 per 1000 CL-days
(95% CI 3.7–5.0), and the lowest rates in the burn ICUs and trauma
ICUs (0.0 and 1.1 per 1000 CL-days, respectively). The difference
between the medical and trauma ICUs was significant (RR 0.86,
95% CI 1.71–8.72, $p = 0.0004$). The DU ratio of CL was higher in
trauma ICUs at 0.41, than in the medical ICUs at 0.18 ($p < 0.001$)
(Tables 2 and 3).

The VAP rate was 20.8 (95% CI 20.4–21.1) in all the ICUs
combined. The highest VAP rate was found in the trauma ICUs:
39.2 per 1000 MV-days (95% CI 33.5–45.5), and the lowest in the
burn ICUs: 7.5 per 1000 MV-days (95% CI 0.1–40.9). However, the
difference in the VAP rates between these ICUs was not significant
($p = 0.06$). The highest MV DU ratio was found in the trauma ICUs:
0.32 (Tables 4 and 5).

Table 1
Features of the participating hospitals, Shanghai, 2004–2009

Variable	Hospital (N = 70)	n (%)
Type of hospital	Academic	33 (47%)
	Public	37 (53%)
Complexity level	Level 2	36 (51%)
	Level 3	34 (49%)
Number of ICPs	1 ICP	34 (49%)
	2–3 ICPs	28 (40%)
	>3 ICPs	8 (11%)

ICP, infection control practitioner.

Table 2

Pooled means and 95% confidence intervals of the distribution of central line-associated blood stream infection rates (per 1000 central line-days) by type of adult and pediatric ICU.

Type of ICU	No. of ICUs	No. of patients	No. of CLABSI	CL-days	Pooled mean CLABSI rate	95% CI
Burn ICU	8	169	0	351	0.0	-
Cardiothoracic ICU	48	61 189	332	166 943	2.0	1.8–2.2
Coronary care ICU	59	88 287	190	59 337	3.2	2.7–3.7
General ICU	47	64 707	719	198 871	3.6	3.4–3.9
Medical ICU	53	24 664	164	38 207	4.3	3.7–5.0
Neurosurgical ICU	43	26 944	145	64 521	2.2	1.9–2.6
Pediatric ICU	19	17 365	68	19 462	3.5	2.7–4.4
Respiratory ICU	48	10 668	84	30 598	2.7	2.2–3.4
Surgical ICU	64	95 491	870	251 631	3.5	3.2–3.7
Trauma ICU	9	2043	6	5394	1.1	0.4–2.4
Overall	398	391 527	2578	835 313	3.1	3.0–3.2

ICU, intensive care unit; CLABSI, central line-associated blood stream infection; CL, central line; CI, confidence interval.

Table 3

Pooled means and 95% confidence intervals of central line utilization ratios by type of adult and pediatric ICU

Type of ICU	No. of ICUs	CL-days	Patient-days	Pooled mean DUR	95% CI
Burn ICU	8	351	663	0.53	0.49–0.57
Cardiothoracic ICU	48	166 943	416 574	0.40	0.39–0.41
Coronary care ICU	59	59 337	691 444	0.09	0.08–0.09
General ICU	47	198 871	655 734	0.30	0.30–0.30
Medical ICU	53	38 207	213 547	0.18	0.18–0.18
Neurosurgical ICU	43	64 521	235 930	0.27	0.27–0.28
Pediatric ICU	19	19 462	195 671	0.10	0.09–0.10
Respiratory ICU	48	30 598	123 524	0.25	0.24–0.25
Surgical ICU	64	251 631	699 138	0.36	0.36–0.36
Trauma ICU	9	5394	13 019	0.41	0.41–0.43
Overall	398	835 313	3 245 243	0.26	0.26–0.26

ICU, intensive care unit; CL, central line; DUR, device use ratio; CI, confidence interval.

Table 4

Pooled means and 95% confidence intervals of the distribution of ventilator-associated pneumonia rates (per 1000 mechanical ventilator-days) by type of adult and pediatric ICU

Type of ICU	No. of ICUs	No. of patients	No. of VAP	MV-days	Pooled mean VAP rate	95% CI
Burn ICU	8	169	1	134	7.5	0.1–40.9
Cardiothoracic ICU	48	61 189	975	78 901	12.4	11.6–13.1
Coronary care ICU	59	88 287	437	25 507	17.1	16.0–18.8
General ICU	47	64 707	4103	165 007	24.9	24.1–25.6
Medical ICU	53	24 664	535	25 219	21.2	19.5–23.1
Neurosurgical ICU	43	26 944	1487	63 360	23.5	22.3–24.7
Pediatric ICU	19	17 365	220	20 806	10.6	9.2–12.1
Respiratory ICU	48	10 668	676	31 186	21.7	20.0–23.4
Surgical ICU	64	95 491	2626	126 230	20.8	20.2–21.6
Trauma ICU	9	2043	164	4186	39.2	33.5–45.5
Overall	398	391 527	11 224	540 535	20.8	20.4–21.1

ICU, intensive care unit; VAP, ventilator associated pneumonia; MV, mechanical ventilator; CI, confidence interval.

Table 5

Pooled means and 95% confidence intervals of mechanical ventilator utilization ratios by type of adult and pediatric ICU

Type of ICU	No. of ICUs	MV-days	Patient-days	Pooled mean DUR	95% CI
Burn ICU	8	134	663	0.20	0.17–0.23
Cardiothoracic ICU	48	78 901	416 574	0.19	0.18–0.19
Coronary care ICU	59	25 507	691 444	0.04	0.04–0.04
General ICU	47	165 007	655 734	0.25	0.25–0.25
Medical ICU	53	25 219	213 547	0.12	0.11–0.12
Neurosurgical ICU	43	63 360	235 930	0.27	0.27–0.27
Pediatric ICU	19	20 806	195 671	0.11	0.10–0.11
Respiratory ICU	48	31 186	123 524	0.25	0.25–0.25
Surgical ICU	64	126 230	699 138	0.18	0.18–0.18
Trauma ICU	9	4186	13 019	0.32	0.31–0.33
Overall	398	540 535	3 245 243	0.17	0.17–0.17

ICU, intensive care unit; DUR: device use ratio; MV, mechanical ventilator; CI, confidence interval.

Table 6

Pooled means and 95% confidence intervals of the distribution of catheter-associated urinary tract infection rates (per 1000 urinary catheter-days) by type of adult and pediatric ICU

Type of ICU	No. of ICUs	No. of patients	No. of CAUTI	UC-days	Pooled mean CAUTI rate	95% CI
Burn ICU	8	169	0	452	0.0	-
Cardiothoracic ICU	48	61 189	206	144 694	1.4	1.2–1.6
Coronary care ICU	59	88 287	1050	82 220	12.8	12.0–13.6
General ICU	47	64 707	2596	297 760	8.7	8.4–9.1
Medical ICU	53	24 664	637	67 243	9.5	8.7–10.2
Neurosurgical ICU	43	26 944	585	129 187	4.5	4.2–4.9
Pediatric ICU	19	17 365	39	14 742	2.6	1.9–3.6
Respiratory ICU	48	10 668	331	41 392	8.0	7.2–8.9
Surgical ICU	64	95 491	1550	312 618	5.0	4.7–5.2
Trauma ICU	9	2043	70	7707	9.1	7.1–11.5
Overall	398	391 527	7064	1 098 013	6.4	6.3–6.6

ICU, intensive care unit; CAUTI, catheter-associated urinary tract infection; UC, urinary catheter; CI, confidence interval.

Table 7

Pooled means and 95% confidence intervals of urinary catheter utilization ratios by type of adult and pediatric ICU

Type of ICU	No. of ICUs	UC-days	Patient-days	Pooled mean DUR	95% CI
Burn ICU	8	452	663	0.68	0.65–0.72
Cardiothoracic ICU	48	144 694	416 574	0.35	0.35–0.35
Coronary care ICU	59	82 220	691 444	0.12	0.12–0.12
General ICU	47	297 760	655 734	0.45	0.45–0.46
Medical ICU	53	67 243	213 547	0.31	0.31–0.32
Neurosurgical ICU	43	129 187	235 930	0.55	0.55–0.56
Pediatric ICU	19	14 742	195 671	0.08	0.07–0.08
Respiratory ICU	48	41 392	123 524	0.34	0.33–0.34
Surgical ICU	64	312 618	699 138	0.45	0.45–0.45
Trauma ICU	9	7707	13 019	0.59	0.58–0.60
Overall	398	1 098 013	3 245 243	0.34	0.34–0.34

ICU, intensive care unit; DUR, device use ratio; UC, urinary catheter; CI, confidence interval.

146 The overall CAUTI rate was 6.4 (95% CI 6.3–6.6). The highest
 147 CAUTI rate was found in the coronary care ICUs: 12.0 per 1000 UC-
 148 days (95% CI 12.0–13.6), and the lowest rates in the burn and
 149 cardiothoracic ICUs: 0.0 and 1.4 per 1000 UC-days, respectively.
 150 The difference between coronary care and cardiothoracic ICUs was
 151 significant regarding the CAUTI rate ($p < 0.001$) and the UC DU
 152 ratio (0.12 in coronary care ICUs compared to 0.35 in cardiotho-
 153 racic ICUs, $p < 0.001$). The highest UC DU ratio was found in the
 154 burn ICUs: 0.68. (Tables 6 and 7).

155 Table 8 shows the DA-HAI rates stratified by hospital size. The
 156 highest CLABSI rate was found in the larger-size hospitals, whose
 157 rate (3.4 per 1000 CL-days) was significantly higher than that in the
 158 medium-size hospitals (2.2 per 1000 CL-days) (RR 1.57, 95% CI
 159 1.43–1.73, $p < 0.001$). The CAUTI rate, however, was higher in the
 160 smaller-size hospitals (8.0 per 1000 UC-days) than in the larger

ones (5.6 per 1000 UC-days) (RR 1.44, 95% CI 1.34–1.55, $p < 0.01$).
 161 VAP rates were similar for all hospital sizes. 162

163 Table 9 shows the evolution of DA-HAI rates by year. It is
 164 noteworthy that the VAP rate improved over the years, decreasing
 165 from 26.0 (24.0–28.2) in 2004 to 15.8 (15.1–16.5) in 2009; this
 166 reduction of 39% was significant (RR 0.61, 95% CI 0.55–0.66,
 167 $p < 0.01$). The CAUTI rate also declined, from 7.4 to 4.9 (RR 0.67,
 168 95% CI 0.59–0.75, $p < 0.001$). However, CLABSI rates remained
 169 stable. We also noticed that the overall VAP rate was higher in the
 170 public hospitals as compared with the academic hospitals (29.5 vs.
 171 17.4, $p < 0.01$), and was also higher in the medium-complexity
 172 hospitals as compared with the high-complexity ones (25.0 vs.
 173 19.0, $p < 0.01$).

174 Table 10 compares overall rates of CLABSI, CAUTI, and VAP (4) in
 175 the INICC Shanghai ICUs and CDC NHSN ICUs. Although NHSN rates

Table 8

Pooled means and 95% confidence intervals of the distribution of device-associated infection rates (per 1000 invasive device-days) by hospital size

Hospital size	No. of patients	CLABSI rate (95% CI)	VAP rate (95% CI)	CAUTI rate (95% CI)
200–500 beds	51 854	3.4 (3.0–3.7)	20.2 (19.1–21.4)	8.0 (7.5–8.6)
501–800 beds	144 669	2.2 (2.0–2.4)	20.9 (20.2–21.6)	7.5 (7.2–7.7)
≥801 beds	194 877	3.5 (3.4–3.7)	20.8 (20.3–21.3)	5.6 (5.4–5.7)

CI, confidence interval; CLABSI, central line-associated blood stream infection; VAP, ventilator associated pneumonia; CAUTI, catheter-associated urinary tract infection.

Table 9

Pooled means and 95% confidence intervals of the distribution of device-associated infection rates (per 1000 invasive device-days) by year

Hospital size	No. of patients	CLABSI rate (95% CI)	VAP rate (95% CI)	CAUTI rate (95% CI)
2004	18 335	3.0 (2.4–3.6)	26.0 (24.0–28.2)	7.4 (6.7–8.2)
2005	65 080	2.5 (2.3–2.8)	23.2 (22.2–24.2)	7.2 (6.8–7.6)
2006	69 010	2.8 (2.5–3.1)	23.6 (22.7–24.7)	7.4 (7.0–7.8)
2007	80 841	2.7 (2.2–3.0)	22.3 (21.5–23.2)	6.4 (6.1–6.7)
2008	78 021	4.3 (4.0–4.6)	19.0 (18.1–19.8)	6.4 (6.1–6.7)
2009	80 249	3.0 (2.7–3.2)	15.8 (15.1–16.5)	4.9 (4.6–5.2)

CI, confidence interval; CLABSI, central line-associated blood stream infection; VAP, ventilator associated pneumonia; CAUTI, catheter-associated urinary tract infection.

Table 10

Comparison of DA-HAI rates (per 1000 device-days) in the ICUs of the International Nosocomial Infection Control Consortium (INICC) Shanghai hospitals and the US National Healthcare Safety Network (US NHSN)

	INICC Shanghai, China 2004–2009 Pooled mean (95% CI)	INICC 2004–2009 Pooled mean (95% CI)	US NHSN 2006–2008 Pooled mean (95% CI)
Medical ICU			
CLABSI	4.3 (3.7–5.0)	14.7 (13.8–15.6)	1.9 (1.8–2.0)
CAUTI	9.5 (8.7–10.2)	6.3 (5.8–6.8)	3.9 (3.7–4.2)
VAP	21.2 (19.5–23.1)	7.7 (7.1–8.3)	2.2 (2.0–2.4)
Surgical ICU			
CLABSI	3.5 (3.2–3.7)	5.0 (4.7–5.4)	2.3 (2.2–2.4)
CAUTI	5.0 (4.7–5.2)	5.0 (4.7–5.4)	4.3 (4.1–4.5)
VAP	20.8 (20.2–21.6)	16.3 (15.7–17.0)	4.9 (4.6–5.1)
Pediatric ICU			
CLABSI	3.5 (2.7–4.4)	10.7 (9.9–11.5)	3.0 (2.8–3.2)
CAUTI	2.6 (1.9–3.6)	4.7 (4.1–5.5)	4.2 (3.8–4.7)
VAP	10.6 (9.2–12.1)	6.5 (5.9–7.1)	1.8 (1.6–2.1)

DA-HAI, device-associated healthcare-associated infections; ICU, intensive care unit; CI, confidence interval; CLABSI, central line-associated bloodstream infection; CAUTI, catheter-associated urinary tract infection; VAP, ventilator-associated pneumonia.

were lower in the medical and surgical ICUs for all infection types, in the pediatric ICUs, the CLABSI rates were similar and the CAUTI rate was higher in the NHSN than in this study (4.2 compared to 2.6 per 1000 UC-days).

Table 11 shows the distribution of the 9043 isolated pathogens involved in device-associated infections. *Acinetobacter baumannii* was the most common microorganism (19.1%), followed by *Pseudomonas aeruginosa*. This indicates that Gram-negative bacteria were the most frequent overall. *Staphylococcus aureus* was the most common organism in CLABSI patients and *Candida spp* in CAUTI patients.

4. Discussion

It has been 30 years since the effectiveness of implementing an integrated infection control program focused on HAI surveillance was demonstrated. As reported in the many studies conducted in the USA, the incidence of HAI may be reduced by as much as 30%, enabling a feasible associated reduction in healthcare costs.²¹ For

Table 11

Distribution of pathogens involved in DA-HAI

Microorganism related to DA-HAI	CLABSI-related (n=845)	VAP-related (n=6151)	CAUTI-related (n=2047)	Overall (n=9043)
<i>Acinetobacter baumannii</i>	12.3%	25.4%	3.0%	19.1%
<i>Pseudomonas aeruginosa</i>	5.1%	23.5%	3.3%	17.2%
<i>Klebsiella pneumoniae</i>	6.9%	14.6%	5.8%	11.9%
<i>Staphylococcus aureus</i>	15.9%	15.0%	1.2%	11.9%
<i>Candida spp</i>	14.0%	1.4%	35.7%	10.4%
<i>Escherichia coli</i>	10.1%	5.1%	19.1%	8.7%
<i>Enterococcus faecium</i>	1.7%	0.0%	13.3%	3.2%
<i>Stenotrophomonas spp</i>	1.9%	4.2%	0.1%	3.1%
<i>Enterobacter spp</i>	3.3%	2.6%	2.4%	2.6%
<i>Enterococcus faecalis</i>	5.1%	0.0%	8.5%	2.4%
Other <i>Staphylococcus</i>	14.1%	0.2%	2.6%	2.0%
Other Gram-negative	2.2%	1.9%	1.3%	1.8%
Other <i>Pseudomonas</i>	1.3%	1.7%	0.7%	1.4%
<i>Proteus spp</i>	0.6%	1.2%	1.1%	1.1%
<i>Flavobacterium spp</i>	0.5%	0.9%	0.1%	0.7%
<i>Streptococcus spp</i>	1.7%	0.0%	0.7%	0.3%
Other pathogens	3.3%	2.1%	1.1%	2.2%

DA-HAI, device-associated healthcare-associated infections; CLABSI, central line-associated blood stream infection; VAP, ventilator-associated pneumonia; CAUTI, catheter-associated urinary tract infection.

more than 30 years, the CDC's NNIS/NHSN network has provided benchmark US ICU data on DAIs and antibiotic resistance, which have proven invaluable for researchers, and have served as an inspiration to the INICC program.^{1,8,22–27} Initially, INICC surveillance was concentrated on DAI surveillance in the ICU, a healthcare setting with the highest HAI rates, in which patient safety is most seriously threatened, due to their critical condition and exposure to invasive devices.²⁸ In our study the most frequently isolated microorganism was *A. baumannii*, followed by *P. aeruginosa*. We had positive sputum culture results from 74% of all study patients with VAP, 25% of which were positive for *Acinetobacter sp*. In a previous study conducted in Hubei, China, *P. aeruginosa* was the most common microorganism, followed by *Escherichia coli* and *A. baumannii*.²⁹ In a different study also carried out in China in 2002, *A. baumannii* was the most common microorganism.³⁰

The rate of device use in Shanghai ICUs is lower than that reported in US ICUs by the NNIS/NHSN system.^{1,25,27} However, DA-HAI rates identified in Shanghai ICUs were higher than the published US rates (Table 9).^{1,27} Although the difference in CLABSI and CAUTI is not considered significant, the VAP rate in Shanghai is particularly high in the ICUs in this study in comparison to the NNIS/NHSN rates. In a recent KISS (Krankenhaus Infektions Surveillance System) study in Germany, the VAP rate was 5.44, which is higher than that reported in the NHSN, but again still much lower than the rate found in our study.³¹

In the surgical ICUs of the Shanghai INICC network, the CLABSI rate was lower than the INICC pooled rates, the CAUTI rate was similar, and the VAP rate was higher. In the medical ICUs of the Shanghai INICC network, the CLABSI rate was lower than the INICC pooled rate, but the CAUTI rate and the VAP rate were higher. In the pediatric ICUs of the Shanghai INICC network, the CLABSI and CAUTI rates were lower than the INICC pooled rates and the VAP rate was higher.¹³

These higher DA-HAI rates may reflect the typical ICU situation in limited-resource countries as a whole.^{32–34} Among the primary plausible causes, it should be mentioned that, in the majority of limited-resource countries, adherence to infection control programs is irregular.

Although few patients receive non-invasive ventilation in the ICU, device utilization rates are low in China. The severity of illness in patients is not frequently evaluated, so patients are not discharged from the ICU in a timely manner, which could partly explain the low utilization rate. To reduce the risk of infection in hospitalized patients, DA-HAI surveillance is of primary importance, because it effectively describes and addresses the importance and characteristics of the threatening situation created by DA-HAIs. This must be followed by the implementation of practices aimed at DA-HAI prevention and control. Additionally, participation in the INICC has played a fundamental role, not only in increasing the awareness of DAI risks in the INICC ICUs, but also in providing an exemplary basis for the institution of infection control practices. In many INICC ICUs, for example, the high incidence of DA-HAI has been reduced by carrying out targeted performance feedback programs for hand hygiene, and central-line, ventilator, and urinary catheter care.^{15,35–41} Finally, to effectively control antibiotic resistance, the administration of anti-infectives must be restricted.

To compare a hospital's DA-HAI rates and DU ratios with the rates identified in this report, it is required that the hospital concerned start collecting their data by applying the methods and methodology described by the CDC NHSN and INICC, and then calculate infection rates and DU ratios for the device-associated module.

The particular and primary application of these data is to serve as a guide for the implementation of prevention strategies and

259 other quality improvement efforts locally, in order to help reduce
260 DA-HAI rates to the minimum possible level.

261 To conclude, the data reported in this study strengthen the fact
262 that DA-HAIs, particularly in ICU patients from low-income
263 countries, must be regarded as a serious and often concealed
264 threat to patient safety, as compared to the developed world. It is
265 the primary objective of the INICC to foster infection control
266 practices by facilitating elemental, feasible, and inexpensive tools
267 and resources to tackle this problem effectively and systematically,
268 leading to greater and stricter adherence to infection control
269 programs and guidelines, and to the correlated reduction in DA-
270 HAI and their adverse consequences in the ICUs participating in the
271 INICC, as well as at any other healthcare facility in the developing
272 world.

273 Acknowledgements

274 The authors thank the many healthcare professionals at each
275 member hospital who assisted with the conduct of surveillance in
276 their hospital, including the surveillance nurses, clinical microbi-
277 ology laboratory personnel, and the physicians and nurses
278 providing care for the patients during the study.

279 Collaborators: Aiguo Zhang, Jiangmeng Luo (Songjian Hospital
280 affiliated to Shanghai Jiaotong University School of Medicine);
281 Yaping Huang, Meijuan Wang (Shanghai 2nd People's Hospital);
282 Chuntao Yi, Xiaoling Xie (Shanghai 8th People's Hospital); Xiaoling
283 Gao, Yingjiu Cai (Shanghai No. 1 People Branch Hospital); Manhong
284 Wang, Rongbei Xie (Ruijin Hospital Luwan Branch); Yuping Du,
285 Dongmei Li (Shanghai Tcm-Integrated Hospital); Ruoyun Shen,
286 Yuyin Guo (Shanghai Dianli Hospital); Xueqing Liu, Mingmin
287 Huang (Shanghai St. Luck's Hospital); Guxiang Ye, Wenwei Yang
288 (Yangpu District Central Hospital); Zhiqiong Zhong, Guoming Zhu
289 (Putuo District People's Hospital); Aiguo Gan (Zhongshan Hospital
290 Cancer Center); Huang Gong (Shanghai Post & Tele Hospital);
291 Fangrui Xu, Fang Feng (Minhang District Central Hospital);
292 Wenhua Zhou, Guangyu Li (Fengxian District Central Hospital);
293 Yun Zhang, Min Xue (Shanghai Jiangong Hospital); Fang Ling,
294 Yuxin Wu (Zhongshan Hospital Qingpu Branch); Huafang Yan,
295 Aihua Mao (Nanhui District Central Hospital); Ruizheng Sun,
296 Haichun Yu (Pla No. 411 Hospital); Jingdi Chen, Jingweng Chen
297 (Shanghai Haiyuan Hospital); Xiaoping Yao, Hui Wen (Jian'an
298 District Center Hospital of Shanghai); Huamin Zhou, Wei Chen
299 (Baogang Hospital Attached No. 2 Shanghai Medical University);
300 Yinling Cheng, Chunjiang Zhao (Changhai Hospital of Shanghai);
301 Junfeng Shi, Lei Li (Xinhua Hospital of Shanghai Second Medical
302 University); Kewei Duo, Lixia Cai (Fudan University Shanghai
303 Cancer Center); Yuejun Wu, Jingquan Li (Eye & Ent Hospital of
304 Fudan University); Jianhua Yu, Xiaohong Gu (Shanghai Municipal
305 Hospital of Traditional Chinese Medicine); Lei Shi (Shanghai Public
306 Health Clinical Center); Qi Shi, Huihua Zhu (Shanghai Chest
307 Hospital affiliated to Shanghai Jiaotong University); Fangyi Weng,
308 Guihong Dong (Longhua Hospital); Xuewen Wang, Guangnan Shao
309 (Yueyan Hospital of Integrated Traditional Chinese And Western
310 Medicine); Hong Yu, Huiying Yang (Shanghai Tenth People's
311 Hospital); Yunfang Zhou, Ruhui Zhang (Shanghai Children's
312 Medical Center); Lei Liu (Shanghai Peoples Armed Police Corps
313 Hospital); Hongli Chen (Shanghai First Hospital For Maternity And
314 Infant Health); Weixiu Wang, Yimian Shen (Putuo District Center
315 Hospital); Jianguo Hao, Hongyu Zhang (Shanghai Seventh People's
316 Hospital); Huiping Wu, Dongping Tang (Changning Center Hospi-
317 tal); Yongli Sun, Biqing Zhu (Yangpu East Hospital); Bo Zhao, Ling
318 Wei (Huashan Hospital Baoshan Fudan University); Yaping Gu,
319 Laifeng Zhu (Renji Hospital Chongming Branch); Jin Miu, Wenqi
320 Zhao (Huangpu District Central Hospital); Aimin Ding, Jinghua Qu
321 (Shanghai Pudong New Area People's Hospital); Zhongxian Song,
322 Jiali Xu (The 455th Hospital of People's Liberation Army);

Chuanqing Wang, Lanzhi Fang (Children's Hospital of Fudan
University); Caiyun Qi, Ying Lu (Obstetrics & Gynecology
Hospital of Fudan University); Xiaohong Li, Ya Zhu (Children's
Hospital of Shanghai); Wenji Fan, Haiwei Chen (Shanghai First
People's Hospital); Yulan Sun, Mingzheng Cai (Hospital of The
Second Military Medical University); Zhizhen Yu, Minhua Cao
(Huadong Hospital affiliated to Fudan University); Zimei Tong,
Peihua Gu (International Peace Maternity And Children's Hospi-
tal of The China Welfare Institute); Qihui Shao, Yi An (Tongji
Hospital of Tongji University); Yindi Wu, Yanhua Mao (Shanghai
Pulmonary Hospital); Yaping Wang, Ying Shen (The Fifth People's
Hospital of Shanghai, Fudan University); Huifang Tan, Yanping
Liu (Shanghai Gongli Hospital); Yanling Yuan, Yan Cao (Shanghai
People's Hospital Baoshan Branch); Baozheng Liu, Meiyang Gao
(Jinshan Central Hospital); Aihua Zhao, Fenghong Li (Zhabei
District Central Hospital); Yanyin Chen, Xiaomei Chen (Shanghai
Xuhui Central Hospital); Weiming Zhang, Zhenmei Tao (Jiading
District Central Hospital of Shanghai); Jianguo Wang, Youdi Qiu
(Jinshan Hospital, Fudan University); Hong Yu, Yaping Wu
(Shanghai Ninth People's Hospital affiliated to Shanghai Jiaotong
University School of Medicine); Qing Lu, Guanghui Li (Shanghai
Huashan Hospital); Qiong Zhang, Shumin Zhao (Shanghai
Changzheng Hospital); Dehuai Shen, Qi Gu (Renji Hospital
Shanghai Second Medical University); Bijie Hu, Xiaodong Gao
(Zhongshan Hospital Fudan University); Li Li, Lei Hua (Shanghai
No. 6 People's Hospital); Xudong Xiong, Hongmei Xu (Shuguan
Hospital); Jianxin Jiang, Min Zhang (Shanghai East Hospital,
Tongji University); Yuxing Ni, Lijun Zhang (Rui Jin Hospital,
Shanghai Jiao Tong University School of Medicine); Hui Zheng,
Ping Yue (Shanghai Mental Health Center).

Conflict of interest: No conflict of interest to declare.

References

1. Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K, Morrell G, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. *Am J Infect Control* 2009;**37**:783-805.
2. Haley RW, Quade D, Freeman HE, Bennett JV. The SENIC Project. Study on the efficacy of nosocomial infection control (SENIC Project). Summary of study design. *Am J Epidemiol* 1980;**111**:472-85.
3. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. *Infect Control Hosp Epidemiol* 1996;**17**:552-7.
4. Fagon JY, Chastre J, Vuagnat A, Trouillet JL, Novara A, Gibert C. Nosocomial pneumonia and mortality among patients in intensive care units. *JAMA* 1996;**275**:866-9.
5. Laupland KB, Zygun DA, Doig CJ, Bagshaw SM, Svenson LW, Fick GH. One-year mortality of bloodstream infection-associated sepsis and septic shock among patients presenting to a regional critical care system. *Intensive Care Med* 2005;**31**:213-9.
6. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. *Am J Infect Control* 1988;**16**:128-40.
7. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *Am J Infect Control* 2008;**36**:309-32.
8. Jarvis WR, Edwards JR, Culver DH, Hughes JM, Horan T, Emori TG, et al. Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. *Am J Med* 1991;**91**(3B):185S-91S.
9. Safdar N, Crnich CJ, Maki DG. Nosocomial infections in the intensive care unit associated with invasive medical devices. *Curr Infect Dis Rep* 2001;**3**:487-95.
10. Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. *Am J Infect Control* 2003;**31**:475-80.
11. Rosenthal VD, Guzman S, Migone O, Safdar N. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: a prospective, matched analysis. *Am J Infect Control* 2005;**33**:157-61.
12. Rosenthal VD, Guzman S, Orellano PW. Nosocomial infections in medical-surgical intensive care units in Argentina: attributable mortality and length of stay. *Am J Infect Control* 2003;**31**:291-5.
13. Rosenthal VD, Maki DG, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. *Am J Infect Control* 2010;**38**:95-104.e2.

- 397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
14. Lynch P, Rosenthal VD, Borg MA, Eremin SR. Infection control in developing countries. In: Jarvis WR, editor. *Bennett and Brachman's hospital infections*. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 255.
 15. Higuera F, Rosenthal VD, Duarte P, Ruiz J, Franco G, Safdar N. The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in Mexico. *Crit Care Med* 2005;**33**:2022-7.
 16. Moreno CA, Rosenthal VD, Olarte N, Gomez WV, Sussmann O, Agudelo JG, et al. Device-associated infection rate and mortality in intensive care units of 9 Colombian hospitals: findings of the International Nosocomial Infection Control Consortium. *Infect Control Hosp Epidemiol* 2006;**27**:349-56.
 17. Madani N, Rosenthal VD, Dendane T, Abidi K, Zeggwagh AA, Abouqal R. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). *Int Arch Med* 2009;**2**:29.
 18. Mehta A, Rosenthal VD, Mehta Y, Chakravarthy M, Todi SK, Sen N, et al. Device-associated nosocomial infection rates in intensive care units of seven Indian cities. Findings of the International Nosocomial Infection Control Consortium (INICC). *J Hosp Infect* 2007;**67**:168-74.
 19. Rosenthal VD, Maki DG, Graves N. The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. *Am J Infect Control* 2008;**36**:e1-2.
 20. Emori TG, Culver DH, Horan TC, Jarvis WR, White JW, Olson DR, et al. National nosocomial infections surveillance system (NNIS): description of surveillance methods. *Am J Infect Control* 1991;**19**:19-35.
 21. Hughes JM. Study on the efficacy of nosocomial infection control (SENIC Project): results and implications for the future. *Chemotherapy* 1988;**34**: 553-61.
 22. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 to June 2002, issued August 2002. *Am J Infect Control* 2002;**30**:458-75.
 23. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. *Am J Infect Control* 2003;**31**:481-98.
 24. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control* 2004;**32**:470-85.
 25. Edwards JR, Peterson KD, Andrus ML, Tolson JS, Goulding JS, Dudeck MA, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007. *Am J Infect Control* 2007;**35**:290-301.
 26. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp Epidemiol* 2008;**29**:996-1011.
 27. Edwards JR, Peterson KD, Andrus ML, Dudeck MA, Pollock DA, Horan TC. National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. *Am J Infect Control* 2008;**36**:609-26.
 28. Rosenthal VD, Maki DG, Salomao R, Moreno CA, Mehta Y, Higuera F, et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. *Ann Intern Med* 2006;**145**:582-91.
 29. Xie DS, Xiong W, Xiang LL, Fu XY, Yu YH, Liu L, et al. Point prevalence surveys of healthcare-associated infection in 13 hospitals in Hubei Province, China, 2007-2008. *J Hosp Infect* 2010;**76**:150-5.
 30. Sun T, Li Y, Hu Y, et al. Retrospective study on clinical features and risk factors of ventilator-associated pneumonia. *Zhonghua Nei Ke Za Zhi* 2002;**41**:468-71.
 31. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database. *Intensive Care Med* 2010;**36**:971-8.
 32. Chandra PN, Milind K. Lapses in measures recommended for preventing hospital-acquired infection. *J Hosp Infect* 2001;**47**:218-22.
 33. Rezende EM, Couto BR, Starling CE, Modena CM. Prevalence of nosocomial infections in general hospitals in Belo Horizonte. *Infect Control Hosp Epidemiol* 1998;**19**:872-6.
 34. Hugonnet S, Harbarth S, Sax H, Duncan RA, Pittet D. Nursing resources: a major determinant of nosocomial infection? *Curr Opin Infect Dis* 2004;**17**:329-33.
 35. Rosenthal VD, Guzman S, Safdar N. Reduction in nosocomial infection with improved hand hygiene in intensive care units of a tertiary care hospital in Argentina. *Am J Infect Control* 2005;**33**:392-7.
 36. Rosenthal VD, Maki DG. Prospective study of the impact of open and closed infusion systems on rates of central venous catheter-associated bacteremia. *Am J Infect Control* 2004;**32**:135-41.
 37. Rosenthal VD, Guzman S, Safdar N. Effect of education and performance feedback on rates of catheter-associated urinary tract infection in intensive care units in Argentina. *Infect Control Hosp Epidemiol* 2004;**25**:47-50.
 38. Rosenthal VD, McCormick RD, Guzman S, Villamayor C, Orellano PW. Effect of education and performance feedback on handwashing: the benefit of administrative support in Argentinean hospitals. *Am J Infect Control* 2003;**31**:85-92.
 39. Rosenthal VD, Guzman S, Pezzotto SM, Crnich CJ. Effect of an infection control program using education and performance feedback on rates of intravascular device-associated bloodstream infections in intensive care units in Argentina. *Am J Infect Control* 2003;**31**:405-9.
 40. Rosenthal VD, Guzman S, Crnich C. Impact of an infection control program on rates of ventilator-associated pneumonia in intensive care units in 2 Argentinean hospitals. *Am J Infect Control* 2006;**34**:58-63.
 41. Rosenthal VD, Maki DG, Rodrigues C, Alvarez-Moreno C, Leblebicioglu H, Sobreyra-Oropeza M, et al. Impact of International Nosocomial Infection Control Consortium (INICC) strategy on central line-associated bloodstream infection rates in the intensive care units of 15 developing countries. *Infect Control Hosp Epidemiol* 2010;**31**:1264-72.
- 442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487